133 related articles for article (PubMed ID: 27810561)
1. BBB penetration-targeting physicochemical lead selection: Ecdysteroids as chemo-sensitizers against CNS tumors.
Müller J; Martins A; Csábi J; Fenyvesi F; Könczöl Á; Hunyadi A; Balogh GT
Eur J Pharm Sci; 2017 Jan; 96():571-577. PubMed ID: 27810561
[TBL] [Abstract][Full Text] [Related]
2. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic considerations in the treatment of CNS tumours.
Motl S; Zhuang Y; Waters CM; Stewart CF
Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
[TBL] [Abstract][Full Text] [Related]
4. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.
Serwer LP; James CD
Adv Drug Deliv Rev; 2012 May; 64(7):590-7. PubMed ID: 22306489
[TBL] [Abstract][Full Text] [Related]
5. The cluster [Re
Estrada LD; Duran E; Cisterna M; Echeverria C; Zheng Z; Borgna V; Arancibia-Miranda N; Ramírez-Tagle R
Biometals; 2018 Aug; 31(4):517-525. PubMed ID: 29574625
[TBL] [Abstract][Full Text] [Related]
6. Do anticancer agents reach the tumor target in the human brain?
Donelli MG; Zucchetti M; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(4):251-60. PubMed ID: 1643692
[TBL] [Abstract][Full Text] [Related]
7. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
8. Semi-synthetic ecdysteroids as gene-switch actuators: synthesis, structure-activity relationships, and prospective ADME properties.
Lapenna S; Dinan L; Friz J; Hopfinger AJ; Liu J; Hormann RE
ChemMedChem; 2009 Jan; 4(1):55-68. PubMed ID: 19065574
[TBL] [Abstract][Full Text] [Related]
9. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
10. Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.
Tosi U; Marnell CS; Chang R; Cho WC; Ting R; Maachani UB; Souweidane MM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208698
[TBL] [Abstract][Full Text] [Related]
11. The Use of Anthracyclines for Therapy of CNS Tumors.
da Ros M; Iorio AL; Lucchesi M; Stival A; de Martino M; Sardi I
Anticancer Agents Med Chem; 2015; 15(6):721-7. PubMed ID: 25846760
[TBL] [Abstract][Full Text] [Related]
12. Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review.
Gvoic M; Vukmirovic S; Al-Salami H; Mooranian A; Mikov M; Stankov K
Pharm Dev Technol; 2021 Jul; 26(6):617-633. PubMed ID: 33882793
[TBL] [Abstract][Full Text] [Related]
13. Ecdysteroids from the Antarctic tunicate Synoicum adareanum.
Miyata Y; Diyabalanage T; Amsler CD; McClintock JB; Valeriote FA; Baker BJ
J Nat Prod; 2007 Dec; 70(12):1859-64. PubMed ID: 18039009
[TBL] [Abstract][Full Text] [Related]
14. Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.
Wager TT; Hou X; Verhoest PR; Villalobos A
ACS Chem Neurosci; 2016 Jun; 7(6):767-75. PubMed ID: 26991242
[TBL] [Abstract][Full Text] [Related]
15. New strategy for alerting central nervous system toxicity: Integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment.
Hallier-Vanuxeem D; Prieto P; Culot M; Diallo H; Landry C; Tähti H; Cecchelli R
Toxicol In Vitro; 2009 Apr; 23(3):447-53. PubMed ID: 19135142
[TBL] [Abstract][Full Text] [Related]
16. 17-Oxime ethers of oxidized ecdysteroid derivatives modulate oxidative stress in human brain endothelial cells and dose-dependently might protect or damage the blood-brain barrier.
Vágvölgyi M; Laczkó D; Santa-Maria AR; Vigh JP; Walter FR; Berkecz R; Deli MA; Tóth G; Hunyadi A
PLoS One; 2024; 19(2):e0290526. PubMed ID: 38386637
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of 20-hydroxyecdysone in mice: relevance to pharmacological effects and gene switch applications of ecdysteroids.
Kumpun S; Girault JP; Dinan L; Blais C; Maria A; Dauphin-Villemant C; Yingyongnarongkul B; Suksamrarn A; Lafont R
J Steroid Biochem Mol Biol; 2011 Aug; 126(1-2):1-9. PubMed ID: 21439380
[TBL] [Abstract][Full Text] [Related]
18. Integrity of blood-brain barrier in primary CNS NK/T cell lymphoma: implications in the treatment of other primary CNS lymphomas.
Chan TS; Pang A; Kwong YL
Ann Hematol; 2016 Jan; 95(2):359-60. PubMed ID: 26482464
[No Abstract] [Full Text] [Related]
19. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Tentori L; Leonetti C; Scarsella M; Vergati M; Xu W; Calvin D; Morgan L; Tang Z; Woznizk K; Alemu C; Hoover R; Lapidus R; Zhang J; Graziani G
Int J Oncol; 2005 Feb; 26(2):415-22. PubMed ID: 15645126
[TBL] [Abstract][Full Text] [Related]
20. Practical uses for ecdysteroids in mammals including humans: an update.
Lafont R; Dinan L
J Insect Sci; 2003; 3():7. PubMed ID: 15844229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
